Cyclodextrin multicomponent complexation and controlled release delivery strategies to optimize the oral bioavailability of vinpocetine

Journal of Pharmaceutical Sciences

Volumn 96, Issue 8, 2007, Pages 2018-2028

  Ribeiro, Laura S S ^a   Falcão, Amílcar C ^a   Patrício, João A B ^b   Ferreira, Domingos C ^c   Veiga, Francisco J B ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Bioavailability; Controlled release; Cyclodextrins; Multicomponent complexes; Vinpocetine

Indexed keywords

CYCLODEXTRIN; HYDROXYPROPYLMETHYLCELLULOSE; TARTARIC ACID; VINPOCETINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RELEASE; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PH; SINGLE DRUG DOSE;

EID: 34548020961     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20294     Document Type: Article

References (35)

1. Subhan Z, Hindmarch I. 1985. Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur J Clin Pharmacol 28:567-571.
2. Bonoczk P, Panczel G, Nagy Z. 2002. Vinpocetine increases blood flow oxygenation in stroke patients: A near infrared spectroscopy and transcranial doppler study. Eur J Ultrasound 15:85-91.
3. Feigin VL, Doronin BM, Popova TF, Gribatcheva EV, Tchernov DV. 2001. Vinpocetine treatment in acute ischaemic stoke: A pilot single-blind randomized clinical trial. Eur J Neurol 8:81-85.
4. McDaniel MA, Maier S, Einstein GO. 2002. "Brain-specific" nutrients: A memory cure? Psychol Sci Pub Int 3:12-38.
5. Szatmari SZ, Whitehouse PJ. 2003. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev 1:CD003119.
6. Grandt R, Beitinger H, Schaltenbrand R, Braun W. 1989. Vinpocetine pharmacokinetics in elderly subjects. Arzneimittelforschung 39:1599-1602.
7. Kostewicz ES, Wunderlich M, Brauns U, Becker R, Bock T, Dressman JB. 2004. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol 56:43-51.
8. Frijlink HW, Eissens AC, Schoonen AJM, Lerk CF. 1990. The effect of cyclodextrin on drug absorption. II. In vivo observations. Int J Pharm 64:195-205.
9. Loftsson T, Másson M, Sirgurjónsdottir JF. 1999. Methods to enhance the complexation efficiency of cyclodextrins. STP Pharma Sci 9:237-242.
10. Loftsson T, Fririksdóttir H, Sigurdardóttir AM, Ueda H. 1994. The effect of water-soluble polymers on drug-cyclodextrin complexation. Int J Pharm 110:169-177.
11. Redenti E, Szente L, Szejtli J. 2000. Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties and pharmaceutical applications. J Pharm Sci 89:1-8.
12. Ribeiro L, Ferreira D, Veiga F. 2003. Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with β-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur J Pharm Sci 20:253-266.
13. Ribeiro L, Carvalho RA, Ferreira DC, Veiga FJB. 2005. Multicomponent complex formation between vinpocetine, cyclodextrins, tartaric acid, and water-soluble polymers monitored by NMR and solubility studies. Eur J Pharm Sci 24:1-13.
14. Wichert B, Rohdewald P. 1990. A new method for the preparation of drug containing polylactic acid microparticles without using organic solvents. J Controlled Release 14:269-283.
15. Savolainen J, Jarvinen K, Matilainen L, Jarvinen T. 1998. Improved dissolution and bioavaibility of phenytoin by sulfobutylether-β- cyclodextrin [(SBE)-β-CD] and hydroxypropyl-β-cyclodextrin. Int J Pharm 165:69-78.
16. 7-β-cyclodextrin in rabbits. J Pharm Sci 88:1016-1020.
17. Charman WN, Porter CJH, Mithani S, Dressman JB. 1997. Physicochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharm Sci 86:269-282.
18. Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB. 1998. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 15:698-705.
19. Nicolaides E, Galia E, Efthymiopoulos C, Dressman JB, Reppas C. 1999. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm Res 16:1876-1882.
20. Kostewicz ES, Brauns U, Becker P, Dressman JB. 2002. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm Res 19:345-349.
21. O'Hara T, Dunne A, Butler J, Devane J. 1998. A review of methods used to compare dissolution profile data. Pharm Sci Technol Today 1:214-223.
22. Moore JW, Flanner HH. 1996. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm Technol 20:64-74.
23. Morelock MM, Choi LL, Bell GL, Wright JL. 1994. Estimation and correlation of drug water solubility with pharmacological parameters required for biological activity. J Pharm Sci 83:948-952.
24. Rao VM, Engh K, Qiu Y. 2003. Design of pH-independent controlled release matrix tablets for acidic drugs. Int J Pharm 252:81-86.
25. FIP. 1996. FIP guidelines for dissolution testing of solid oral products (final drafts, 1995). Drug Inf J 30:1071-1084.
26. Bibby DC, Davies NM, Tucker IG. 2000. Mechanism by which cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharm 197:1-11.
27. Ribeiro L, Loftsson T, Ferreira D, Veiga F. 2003. Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether β-cyclodextrin binary and ternary complexes. Chem Pharm Bull 51:914-922.
28. Luengo J, Aránguiz T, Sepúlveda J, Hernández L, Von Plessing C. 2002. Preliminary pharmacokinetic study of different preparations of acyclovir with β-cyclodextrin. J Pharm Sci 91:2593-2598.
29. Hasan EI, Amro BI, Arafat T, Badwan AA. 2003. Assessment of a controlled release hydrophilic matrix formulation for metoclopramide HCl. Eur J Pharm Biopharm 55:339-344.
30. Savolainen J, Jarvinen K, Taipale H, Jarho P, Loftsson T, Jarvinen T. 1998. Co-administration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms. Pharm Res 15:1696-1701.
31. Panchagnula R, Thomas NS. 2000. Biopharmaceutics and pharmacokinetics in drug research. Int J Pharm 201:131-150.
32. Ngo TH, Quintens I, Roets E, Declerck PJ, Hoogmartens J. 1997. Bioavailability of different artemisinin tablet formulation in rabbit plasma: Correlation with results obtained by an in vitro dissolution method. J Pharm Biomed Anal 16:185-189.
33. Dollo G, Le Corre P, Guerin A, Chevanne F, Burgot JL, Leverge R. 2003. Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. Eur J Pharm Sci 19:273-280.
34. Fernandes C, Ramos P, Falcão AC, Veiga F. 2003. Hydrophilic and hydrophobic cyclodextrin in a new sustained release oral formulation of nicardipine: In vitro evaluation and bioavailability studies in rabbits. J Controlled Release 88:127-134.
35. Zwart LL, Rompelberg CJM, Sips AJAM, Van Engelen JGM. 1999. Anatomical and physiological differences between various species used in studies on the pharmacokinetics and toxicology of xenobiotics. Bilthoven: RIVM Report 623860610, pp 1-100.